WARSAW, Poland -- June 11, 2009 -- According to a meta-analysis presented here at the 28th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), both subcutaneous (SCIT) and sublingual allergen-specific immunotherapy (SLIT) lead to substantial reductions in rhinitis and conjunctivitis symptoms in patients with grass pollen allergy, but the probability for systemic or anaphylactic reactions is higher with the subcutaneous administration.
Similar decreases were seen in both groups in terms of frequency and severity of conjunctivitis symptoms. "The total rhinoconjunctivitis score was significantly reduced in both groups by about 50%," Dr. Sieber said (P < .001 with both SLIT and SCIT). "There was no significant difference between the 2 treatment forms."
Adverse events occurred mainly during the titration phase and abated during the maintenance phase. This observation matches the known event pattern. As Dr. Sieber pointed out, no severe systemic or anaphylactic reactions arose with the SLIT treatment, whereas with SCIT, one severe systemic reaction and one anaphylactic reaction occurred during the titration phase."
In terms of efficacy, SCIT and SLIT are comparable," Dr. Sieber summarised. "As SLIT appears more tolerable, we think that it should be used preferentially for the treatment of pollen allergies."
http://www.docguide.com/news/content.nsf/news/852571020057CCF6852575D20063235A
Subscribe to:
Post Comments (Atom)
Mother and daughter getting allergy skin tests. Click on the photo to see a You Tube interview with another parent and child.
No comments:
Post a Comment